Author Archives: Alexis BERNARD

AB Science has received approval from the U.S. Food and Drug Administration (FDA) to initiate the confirmatory Phase 3 study with masitinib in the treatment of progressive multiple sclerosis

29/12/2022 – AB Science announced today that its Phase III clinical trial (AB20009) in progressive forms of multiple sclerosis has been approved by the US Food and Drug Administration (FDA)

Masitinib receives orphan drug status for the treatment of amyotrophic lateral sclerosis in Switzerland

27/12/2022 – AB Science today announces that masitinib has been granted orphan drug status (ODS) by the Swiss Agency for Therapeutic Products (Swissmedic) for the treatment of patients with amyotrophic lateral sclerosis (ALS)

AB Science announces the drawdown of the first tranche of 6 million euros under its financing agreement with the European Investment Bank

22/12/2022 – AB Science announced today that it has received payment of €6.0 million as the first tranche of a €15 million loan from the European Investment Bank (EIB)

AB Science receives Notice of Deficiency (NOD) from Health Canada for masitinib in the treatment of amyotrophic lateral sclerosis (ALS)

13/12/2022 – AB Science announced that it has received a Notice of Deficiency (“NOD”) for its masitinib New Drug Submission in the treatment of amyotrophic lateral sclerosis

AB Science receives U.S. Food and Drug Administration (FDA) authorization to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s Disease

21/11/2022 – AB Science today announced that it has received an Investigational New Drug (IND) approval letter from the FDA to initiate Phase III study (AB21004) in patients with mild to moderate Alzheimer’s disease

AB Science receives first agencies authorizations to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s disease

10/10/2022 – AB Science today announces that the first authorizations have been received to initiate its phase 3 confirmatory study (AB21004) evaluating masitinib in patients with mild to moderate Alzheimer’s Disease

Revenues for the first half of 2022 and update on AB Science’s activities

30/09/2022 – AB Science today reports its revenues for the first half of 2022 and provides an update on its activities

Positive recommendation of the Data and Safety Monitoring Board to continue the Phase 2 study evaluating the antiviral activity of masitinib in Covid-19

14/09/2022 – AB Science announced continuation of the Phase 2 study evaluating the antiviral activity of masitinib in patients who have a confirmed diagnosis of COVID-19, following the recommendation of the Data and Safety Monitoring Board (DSMB)

AB Science announces that it has filed an application for conditional Marketing Authorization to EMA for masitinib in the treatment of ALS

24/08/2022 – AB Science today announced that it has filed an application for conditional Marketing Authorization to the European Medicines Agency (EMA) for Alsitek (masitinib) in the treatment of amyotrophic lateral sclerosis (ALS)

Publication of results from the positive study of masitinib in severe asthma uncontrolled by oral corticosteroids in Journal of Asthma and Allergy

07/06/2022 – AB Science today announced the publication of results from its positive study of masitinib in severe asthma uncontrolled by oral corticosteroids (OCS) in the peer-reviewed Journal of Asthma and Allergy